These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Löffler W; Kilian R; Toumi M; Angermeyer MC Pharmacopsychiatry; 2003 May; 36(3):105-12. PubMed ID: 12806568 [TBL] [Abstract][Full Text] [Related]
24. [Subjective perception of the effect of neuroleptics by outpatient schizophrenic patients: a cross-sectional study]. Bonsack C; Conus P; Philippoz R; Bovet J; Spagnoli J; Dufour H Encephale; 1998; 24(4):315-23. PubMed ID: 9809236 [TBL] [Abstract][Full Text] [Related]
25. A prototype approach toward antipsychotic medication adherence in schizophrenia. Freudenreich O; Tranulis C Harv Rev Psychiatry; 2009; 17(1):35-40. PubMed ID: 19205965 [TBL] [Abstract][Full Text] [Related]
26. Compliance with antipsychotic treatment. Oehl M; Hummer M; Fleischhacker WW Acta Psychiatr Scand Suppl; 2000; (407):83-6. PubMed ID: 11261648 [TBL] [Abstract][Full Text] [Related]
27. Psychosocial and socio-demographic correlates of medication compliance among people with schizophrenia. Tsang HW; Fung KM; Corrigan PW J Behav Ther Exp Psychiatry; 2009 Mar; 40(1):3-14. PubMed ID: 18417098 [TBL] [Abstract][Full Text] [Related]
28. [Drug compliance and health locus of control in schizophrenia]. Combes C; Feral F Encephale; 2011 May; 37 Suppl 1():S11-8. PubMed ID: 21600328 [TBL] [Abstract][Full Text] [Related]
29. Subjective response to neuroleptics in schizophrenia. Awad AG Schizophr Bull; 1993; 19(3):609-18. PubMed ID: 7901897 [TBL] [Abstract][Full Text] [Related]
30. Negative symptoms of schizophrenia and compliance with medication. Tattan TM; Creed FH Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543 [TBL] [Abstract][Full Text] [Related]
32. [Viewpoint of schizophrenic patients: a European survey]. Courtet P Encephale; 2001; 27(1):28-38. PubMed ID: 11294036 [TBL] [Abstract][Full Text] [Related]
34. Understanding and addressing adherence issues in schizophrenia: from theory to practice. Weiden PJ J Clin Psychiatry; 2007; 68 Suppl 14():14-9. PubMed ID: 18284273 [TBL] [Abstract][Full Text] [Related]
35. [Relationships between insight and medication adherence in subjects with psychosis]. Droulout T; Liraud F; Verdoux H Encephale; 2003; 29(5):430-7. PubMed ID: 14615692 [TBL] [Abstract][Full Text] [Related]
36. [Adherence to neuroleptic treatment of schizophrenic patients]. Blondiaux I; Alagille M; Ginestet D Encephale; 1988; 14(6):431-8. PubMed ID: 2906607 [TBL] [Abstract][Full Text] [Related]
37. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists]. Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914 [TBL] [Abstract][Full Text] [Related]
38. [What information do patients with schizophrenia have about their illness and treatment?]. Ferreri M; Rouillon F; Nuss P; Bazin N; Farah S; Djaballah K; Gerard D Encephale; 2000; 26(5):30-8. PubMed ID: 11192802 [TBL] [Abstract][Full Text] [Related]
39. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Lindström E; Bingefors K Pharmacoeconomics; 2000 Aug; 18(2):106-24. PubMed ID: 11067646 [TBL] [Abstract][Full Text] [Related]
40. [Attitude of family to neuroleptics]. Angermeyer MC; Matschinger H Psychiatr Prax; 1999 Jul; 26(4):171-4. PubMed ID: 10457968 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]